Helus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targetsHelus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targets

Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus

2026/05/01 21:05
2분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs, though the company reaffirmed the collaboration’s alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.

The partnership is designed to support Phase 3 recruitment for Helus Pharma’s HLP003 program, which targets major depressive disorder, and to expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is currently enrolling patients for Phase 3 clinical development of HLP003 as an adjunctive treatment for major depressive disorder.

Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to developing synthetic molecules that activate serotonin pathways to promote neuroplasticity. The company’s proprietary NSAs are intended to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. In addition to HLP003, Helus Pharma is developing HLP004, another proprietary NSA in Phase 2 clinical development for generalized anxiety disorder.

The correction follows the company’s earlier announcement and clarifies the scope of the partnership with TARA Mind. The original press release can be viewed at https://ibn.fm/re8HL. Helus Pharma continues to operate in Canada, the United States, the United Kingdom, and Ireland, and provides updates on its website at www.helus.com.

The company’s newsroom, available at https://ibn.fm/HELP, provides the latest updates on its programs and initiatives. Helus Pharma’s focus on serotonergic agonists aims to improve the treatment landscape for mental health conditions by offering durable improvements through neuroplasticity.

This correction highlights the importance of accurate communication in clinical-stage pharmaceutical companies, especially when partnerships involve sensitive populations such as veterans. The alignment with the executive order underscores the broader push to enhance mental health treatments and increase clinical research participation among underserved groups.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus.

The post Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Veteran Outreach Focus appeared first on citybuzz.

시장 기회
타락사 코인 로고
타락사 코인 가격(TARA)
$0.00002079
$0.00002079$0.00002079
+0.92%
USD
타락사 코인 (TARA) 실시간 가격 차트

Predict & Trade to Win Rewards

Predict & Trade to Win RewardsPredict & Trade to Win Rewards

Guaranteed rewards with $500,000 prize pool

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage